919 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
TEVA Teva Pharmaceutical Industries Limited $23.43 $23.86B N/A
Article Searches
Teva: Outstanding Buying Opportunity Ahead https://seekingalpha.com/article/4058035-teva-outstanding-buying-opportunity-ahead?source=feed_tag_israel Mar 27, 2017 - Allergan's lock-up of 100M in Teva shares expires in August.I dig into AGN's SEC filings to find out if the company plans to sell the shares immediately after the lock-up expires.After concluding that
Teva Pharma Denies Rumors of Global Workforce Reduction http://www.zacks.com/stock/news/254066/teva-pharma-denies-rumors-of-global-workforce-reduction?cid=CS-ZC-FT-254066 Mar 24, 2017 - According to recent reports, Teva Pharmaceutical Industries Ltd (TEVA) is likely lay off almost 11% of its global workforce to cut costs and improve growth prospects.
Allergan's Restasis Now Available in Multidose Bottle in U.S. http://www.zacks.com/stock/news/253868/allergans-restasis-now-available-in-multidose-bottle-in-us?cid=CS-ZC-FT-253868 Mar 23, 2017 - Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.
Teva Pharm may fire 6,000 workers http://seekingalpha.com/news/3252919-teva-pharm-may-fire-6000-workers?source=feed_news_all Mar 23, 2017 - Teva Pharmaceutical (NYSE:TEVA) plans to cut as many as 6,000 jobs, or about 11% of its global workforce, Israel's Calcalist reports.It has had a rough year, with a serious of costly acquisitions, alo
Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod http://www.zacks.com/stock/news/253593/allergans-dermal-filler-for-wrinkle-correction-gets-fda-nod?cid=CS-ZC-FT-253593 Mar 21, 2017 - Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.
Nektar's Pain Drug Positive in Phase III Study; Shares Gain http://www.zacks.com/stock/news/253567/nektars-pain-drug-positive-in-phase-iii-study-shares-gain?cid=CS-ZC-FT-253567 Mar 21, 2017 - Nektar Therapeutics??? (NKTR) shares surged 42.6% after the company announced positive results from a phase III efficacy study evaluating its investigational candidate, NKTR-181, in patients with moderate to severe chronic low back pain.
AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal http://www.zacks.com/stock/news/253385/astrazeneca-azn-gets-another-crl-for-zs-9-inks-copd-deal?cid=CS-ZC-FT-253385 Mar 20, 2017 - London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.
Teva Launches Authorized Generic of Allergan's Minastrin http://www.zacks.com/stock/news/253207/teva-launches-authorized-generic-of-allergans-minastrin?cid=CS-ZC-FT-253207 Mar 17, 2017 - Teva Pharmaceutical Industries Ltd. (TEVA) recently launched an authorized generic version of Allergan plc???s (AGN) oral contraceptive, Minastrin 24 Fe1, in the U.S.
Teva's Chorea Approval And Osteoporosis Data For Amgen http://seekingalpha.com/article/4054231-tevas-chorea-approval-osteoporosis-data-amgen?source=feed_sector_healthcare Mar 10, 2017 - Welcome to your weekly digest of approaching regulatory and clinical readouts. Teva (NYSE:TEVA) expects a US decision on SD-809, its possible treatment for Huntington’s chorea, at the beginning of Apr
Teva-Takeda Japanese Joint Venture Adds $450M Revenue For Q4 http://seekingalpha.com/article/4046364-teva-takeda-japanese-joint-venture-adds-450m-revenue-q4?source=feed_tag_israel Feb 15, 2017 - Teva's joint venture with long-time Japanese OTC drug company Takeda began during 2016.The joint venture added $450M in generics revenue during the 4th Quarter of 2016.TEVA looks set to continue growi

Pages: 1...8283848586878889909192

<<<Page 87>